Slide 1: EAACI Congress 2024
EAACI Congress 2024 Valencia, Spain 31 May - 3 June Revolutionising Patient Care Through the Power of Data Science ein | | OMe Ray | HEED | ooe@one #EAAClIcongress www.eaaci.org
Slide 2: Briquilimab Effectively Treats Epicutaneous Allergen-Induced Atopic Dermatitis in Mouse Model
Briquilimab, an Anti-Human CD117 Antibody, Effectively Treats Epicutaneous Allergen- Induced Atopic Dermatitis in Mouse Model Expressing Chimeric Human/Mouse CD117 Mang Yu, M.D., Ph.D. Jasper Therapeutics, Inc., Redwood City, CA, USA 02 June 2024
Slide 3: Disclosure of Conflict of Interest
Disclosure of Conflict of Interest The authors have no conflict of interest to disclose.
Slide 4: Table of Content
Table of Content 1 Briquilimab 2 Chimeric Human/Mouse CD117 Mice 3 Prophylactic Treatment Model 4 Therapeutic Treatment Model 5 Conclusions 6 Takeaways 7 Acknowledgements
Slide 5: Briquilimab, an Anti-human CD117 mAb, Potently Regulates Mast Cell Survival and Functions
1 Briquilimab (Briq), an Anti-human CD117 mAb, Potently Regulates Mast Cell (MC) Survival and Functions through Inhibiting SCF-CD117 Signaling.
Slide 6: h/mCD117 mice provide a robust tool for evaluating mast cell depletion
h/mCD117 mice, expressing chimeric functional human and murine CD117, provide 2 a robust tool for evaluating briquilimab-mediated mast cell (MC) depletion and its therapeutic effect on MC-related diseases including atopic dermatitis. Control Briq MC Depletion Toluidine Blue (MCs) Significant MC depl
Slide 7: Prophylactic Treatment Model Using h/mCD117 Mice
3.1 Prophylactic Treatment Model Using h/mCD117 Mice to Test Briquilimab’s Proof-of-Concept Efficacy for Atopic Dermatitis. Briquilimab prophylaxis HDM/SEB sensitization (50 mg/kg, i.p.) HDM/SEB challenge Naïve (10/0.5 mcg, e.c. back patch) 🔍📸 (10/0.5 mcg, e.c. back patch) 🔍📸 h/m CD117 Necropsy…
Slide 8: Prophylactic treatment reduced mast cells, symptoms, and dermal inflammation
3.2 Two weeks after one-time Briq prophylactic treatment, epicutaneous allergen- sensitized h/mCD117 mice exhibited significantly reduced dorsal skin MC number, symptoms, and dermal inflammation following epicutaneous allergen challenge. Symptom Severity Dorsal Skin Thickness Placebo Briq Prophylaxi
Slide 9: Therapeutic Treatment Model Using h/mCD117 Mice
4.1 Therapeutic Treatment Model Using h/mCD117 Mice to Test Briquilimab’s Proof- of-Concept Efficacy for Atopic Dermatitis Briquilimab therapy h/m CD117 HDM/SEB sensitization HDM/SEB challenge (50 mg/kg, i.p.) Naïve (10/0.5 mcg, e.c. back patch) mice with AD (10/0.5 mcg, e.c. back patch) symptoms…
Slide 10: Therapeutic treatment reduced mast cells, symptoms, and dermal inflammation
Two weeks after one-time Briq therapeutic treatment, established atopic dermatitis 4.2 models in h/mCD117 mice exhibited significantly reduced dorsal skin MCs, symptoms, and dermal inflammation. Symptom Severity Dorsal Skin Thickness Placebo Briq Therapy ∆Skinfold Thickness Toluidine Blue (MCs) 12 3
Slide 11: Conclusions
5 CONCLUSIONS § A single dose of briquilimab can deplete mast cells (MCs) in healthy h/mCD117 mice or atopic dermatitis model elicited in h/mCD117 mice. § Briquilimab’s ability to deplete MCs contributes to its prophylactic and therapeutic effect on atopic dermatitis model induced in h/mCD117 mice.
Slide 12: Takeaways
6 TAKEAWAYS § Mast cells (MCs) play a critical role in the pathogenesis of atopic dermatitis. § Briquilimab can potentially target MCs in the treatment for atopic dermatitis. § JASPER is actively enrolling participants in two phase 1b/2a trials evaluating briquilimab in patients with chronic spontan
Slide 13: Acknowledgements
7 ACKNOWLEDGEMENTS Jasper Therapeutics, Inc. Stanford University Wendy W. Pang Edwin Tucker Stephen J. Galli Hye-Sook Kwon Daniel Adelman Judy Shizuru Kavitha Arulprakasam Patricia Carlos Sambidhan Kattel Ryan Taylor University of Southern California Andrew Wells Anne Le Fu-Tong Liu Revati Nerkar Aa